OAM
FLNA

Oxford Asset Management’s Filana Therapeutics FLNA Stock Holding History

Oxford Asset Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-30,778
Closed -$26K – 1941
2018
Q4 		$26K Buy
+30,778
New +$35.4K ﹤0.01% 1731

Other funds holding FLNA

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Oxford Asset Management's FLNA Position: Q1 2019 in Review

Oxford Asset Management sold out of Filana Therapeutics (FLNA) in Q1 2019, closing a stake of 30,778 shares — an estimated $26K sold.

Oxford Asset Management first reported a position in FLNA in Q4 2018 and held it in 1 quarter. The position peaked at $26K in Q4 2018. 27 funds tracked by Wall St. Rank hold FLNA as of Q1 2019.

  • Oxford Asset Management reported no remaining Filana Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Oxford Asset Management sold 30,778 Filana Therapeutics shares in Q1 2019, an estimated $26K.
  • Oxford Asset Management first reported a position in Filana Therapeutics in Q4 2018 and held it in 1 quarter.
  • Oxford Asset Management's Filana Therapeutics position peaked at $26K in Q4 2018.
  • 27 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.